-
Published 6/2/2023
Olivier T, Smith CEP, Haslam A, Addeo A, Prasad V. Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022. J Cancer Policy. 2023 Sep; 37:100426. PMID: 37270063.
-
Published 9/10/2022
Smith CEP, Marcom PK, Mitri Z, Ko NY. Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. Breast Cancer Res Treat. 2022 Nov; 196(1):215-220. PMID: 36087190.
-
Published 5/3/2021
Smith CEP, Prasad V. Assessment of New Molecular Entities Approved for Cancer Treatment in 2020. JAMA Netw Open. 2021 05 03; 4(5):e2112558. PMID: 34047795.
-
Published 2/18/2021
West MT, Smith CE, Kaempf A, Kohs TCL, Amirsoltani R, Ribkoff J, Choung JL, Palumbo A, Mitri Z, Shatzel JJ. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol. 2021 May; 106(5):634-642. PMID: 33527479.
-
Published 2/1/2021
Smith CEP, Prasad V. Targeted Cancer Therapies. Am Fam Physician. 2021 02 01; 103(3):155-163. PMID: 33507053.